Login to Your Account



Clinic Roundup


Tuesday, May 15, 2012
• Fibrocell Science Inc., of Exton, Pa., said it submitted to the FDA its Phase II protocol for testing lead therapy azficel-T in improving the range of motion, function and flexibility in patients with existing restrictive burn scars. Azficel-T, an autologous cell therapy, previously gained approval as LaViv for reducing the appearance of moderate to severe nasolabial fold wrinkles.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription